PE22
PE-22-28 is a synthetic seven-amino-acid analog of spadin (PE 12-28), a sortilin propeptide fragment, and acts by blocking TREK-1 potassium channels. In mice it has shown antidepressant-like effects and neurogenesis.
5 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
PE-22-28 is a compound studied only in animals and lab experiments so far. PE-22-28 is a synthetic seven-amino-acid analog of spadin (PE 12-28), a sortilin propeptide fragment, and acts by blocking TREK-1 potassium channels.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection, Intranasal |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsi.p. dosing in mice (forced swim, novelty-suppressed feeding; 4-day sub-chronic); exact µg/kg in full textCommunity-reportedCommunity-reported: 50–100 mcg, subcutaneous injection, Intranasal |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It blocks a brain potassium channel called TREK-1 and showed antidepressant-like effects in mice. Proposed mechanism, from cell and mouse studies: a shortened analogue of spadin that inhibits the TREK-1 potassium channel, with better TREK-1 inhibition, in vivo stability and antidepressant-like activity in mouse behavioural models than spadin (Djillani 2017; review, Djillani 2019).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedSome users report running PE-22-28 at 50–100 mcg (subcutaneous injection, intranasal). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
PE-22-28 is a seven-amino-acid analog of spadin (PE 12-28), a fragment of the sortilin propeptide. It is not derived from Cerebral Dopamine Neurotrophic Factor (CDNF). It acts as a TREK-1 potassium channel inhibitor (IC50 0.12 nM in hTREK-1/HEK cells). In mouse studies it showed antidepressant-like effects and neurogenesis, with antidepressant action lasting up to 23 hours versus 7 hours for spadin. No human studies have been published. It has become popular in the biohacking community as a nootropic peptide.
Pro-Glu-Lys-Arg-Pro-Val-Ala (7 amino acids)
Molecular Weight: 796.9 Da
Molecular Formula: C35H63N11O10
Structure Details: Linear heptapeptide derived from the C-terminal region of CDNF protein (residues 22-28). Contains a proline at both termini contributing to structural stability.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| PE-22-28 | No published PK data found | Subcutaneous injection, Intranasal | Preclinical (animal) |
| Dihexa | Unknown | Oral or intraperitoneal (rodent studies only); no human administration published | Preclinical (animal) |
| FGL (L) | Unknown | Subcutaneous injection | Preclinical (animal) |
| P21 | Unknown | Oral (mice) | Preclinical (animal) |
| Pinealon | No published PK data found | Oral, Sublingual | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Cognitive category. View All Cognitive Peptides
Anti-Aging
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.